SOLICITATION NOTICE
R -- R-Chromotography Assay
- Notice Date
- 2/8/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Room 604, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- RFQ-NCI-20035-NQ
- Response Due
- 2/15/2002
- Archive Date
- 3/2/2002
- Point of Contact
- Cynthia Brown, Purchasing Agent, Phone (301) 496-8608, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
cb106x@nih.gov, rasmusc@mail.nih.gov
- Description
- The National Institute of health, National Cancer Institute(NCI), Dermatology Branch, Center for Cancer Research, has an urgent need to apply the nuclease P1-enhanced 32P-postlabeling chromatography assay of Dr. Kurt Randerath for the detection of I-compounds in cultured cells from patients with various neurodegenerations. The required services can only be obtained from Covance Laboratories Inc., under the directoin of Dr. Raghu G. Nath, 9200 Leesburg Pike, Vienna, VA 22182. This requirement is being procured under the statutory authority contained in U.S. C. 253(c)(1), and in accordnace with the FAR 6.302-1(a)(2). The Dermatology Branch wishes to conduct 32P-postlabeling chromatography assays for I-compounds in DNA samples. It is the only method known to Center for Cancer Research (DB) that can detect the I-compounds believed to cause the neurodegeneration in Alzheimer disease. These studies will lead to diagnostic test for sporadic Alzheimer disease and to antioxidants that can prevent the neurodegeneration. The Center for Cancer Resarch (DB) wishes to establish the presence of one or more of these unrepaired lesions in these diseases. Dr. Kurt Randerath's postlabeling assay will assist in determining whether any oxidative lesion is repaired abnormally in Alzheimer disease cells. This is the only assay known to the Cancer Research Center that can provide the answers that DB seeks, since it detects structurally unknown oxidative lesions, any of which may be the offending damage in Alzheimer disease. Furthermore, it can detect as few as 1-5 lesions per cell and is therefore, the most sensitive assay for lesion detection. Dr. Raghu G. Nath undertook his post-doctoral fellowship under Dr. Randerath and has published several peer-reviewed papers. Dr. Nath heads the DNA Interactions Unit at Covance Laboratories Inc., Vienna, VA, his lab has the required equipment, chemicals and expertise to conduct these postlabeling experiments. Dr. Nath's expertise is necessary in order for DB to build upon the data already obtained, so as to avoid incorrect interpretation of the experiments being planned. It is expected that some 120 to 180 DNA samples be assayed under these conditions. Therefore, the Center for Cancer Research, NCI, DB believes that Covance Lab. Inc., Dr. Raghu G. Nath is the only known source that is uniquely situated and experienced to carry out the requirements. This notice of intent is nt a request for competitive quotations. However, if any intrested party believes it can provide the above services, including data and demonstrated expertise, it may submit a statement of capabilities. The capability statement and any information must be in writing and must contain material in sufficient detail to allow NCI research to determine if the party can fully meet this requirement. Capability statements must be received in the contracting office by 1:30 PM EDT (local Washington, DC time on February 15, 2002. If there are any questions please contact Cynthia Brown, Purchasing Agent at (301) 402-4509. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive requirement. NAICS Code 541380. Business size standard $5M. NOTE: Due the the temporary relocation of the NCI/RCB/PSAS from 6120 Executive Blvd., Rm. 634, Rockville, MD 20892, we ask that any and all capability statements be sent to NCI/RCB/PSAS, 6116 Executive Blvd., Room 205, Rockville, MD 20892 until further notice.
- Record
- SN00024409-W 20020210/020208213120 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |